fda warning compounded semaglutide october 2025 Important Update: Changes to Availability FDA warns against compounded GLP-1

Dual-peptide formulation with quantified ratio Designed for combination pathway interaction studies Stabilized structures for extended assay duration Suitable for comparative and multi-variable research protocols This preparation is frequently selected for investigative frameworks requiring accurate peptide ratios and consistent molecular performance across testing phases

Clinicians are faced with untangling many differences in trial design and patient characteristics, and an absence of any direct head-to-head insights

GLP-1 receptor agonists, originally developed for diabetes and weight management, are emerging as promising non-hormonal options to reduce cardiovascular risk in estrogen-deficient women

Ries, L

2 Everyone in the 26-week trial also received cognitive behavioral therapy